Aridis Pharmaceuticals Stock (NASDAQ:ARDS)


OwnershipChart

Previous Close

$NaN

52W Range

- - $0.09

50D Avg

-

200D Avg

$0.04

Market Cap

$4.46K

Avg Vol (3M)

$5.64K

Beta

-26.04

Div Yield

-

ARDS Company Profile


Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

37

IPO Date

Aug 14, 2018

Website

ARDS Performance


Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
HOTHHoth Therapeutics, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
ABVCABVC BioPharma, Inc.
ADTXAditxt, Inc.
REVBRevelation Biosciences, Inc.
RNAZTransCode Therapeutics, Inc.
AKTXAkari Therapeutics, Plc
SGTXSigilon Therapeutics, Inc.
DRMADermata Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
KODKodiak Sciences Inc.
EYENEyenovia, Inc.
NRBONeuroBo Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
ACSTAcasti Pharma Inc.
CGTXCognition Therapeutics, Inc.
ATXIAvenue Therapeutics, Inc.